Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH.
Zobair M YounossiKamal Kant ManglaAbhishek Shankar ChandramouliJeffrey Victor LazarusPublished in: Hepatology communications (2024)
Comorbidities, such as cardiovascular disease and type 2 diabetes, are associated with a higher cost burden and may be aggravated by MASH. Prioritization and active management may benefit patients without cirrhosis with these comorbidities. Clinical care should focus on preventing progression to cirrhosis and managing high-burden comorbidities.
Keyphrases
- type diabetes
- cardiovascular disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- risk factors
- palliative care
- prognostic factors
- quality improvement
- coronary artery disease
- metabolic syndrome
- patient reported outcomes
- adipose tissue
- chronic pain
- cardiovascular events
- cardiovascular risk factors